Lupin gets US FDA approval for Ranluspec biosimilar ranibizumab

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.4%Reaction day

₹2252.00

prior close

₹2275.40

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.3%+0.6% vs market

Pharmaceuticals peers, median of 164sector+0.0%+0.3% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty Midcap 150 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.9

10m

+0.9

15m

+0.5

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.4-0.3+0.6+0.0+0.3

Next day

-0.2-1.7+1.6-0.8+0.7

+0.5-0.4+0.9+0.3+0.2

-0.2-1.8+1.6+0.0-0.2

+1.0-2.6+3.6-0.6+1.6

+1.7-0.3+2.0+0.5+1.2

+0.9+1.6-0.7+1.0-0.1

15d

+6.5+1.6+4.8+4.3+2.2

+10.6+2.9+7.6+5.4+5.1

+5.8+4.9+0.9+4.7+1.1

-6.6+3.3-9.9+8.9-15.5

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin received US FDA approval for Ranluspec, its interchangeable biosimilar referencing Lucentis. It is the only interchangeable biosimilar ranibizumab approved in the US in both vials and pre-filled syringes, across 0.3 mg and 0.5 mg strengths. The drug treats eye conditions including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. This is Lupin's second US biosimilar, strengthening its complex biologics portfolio.

Likely market impact

Positive for Lupin as the approval expands its US biosimilars portfolio and opens a new revenue stream in a high-value therapy area.